Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients

Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients

Multiple myeloma survival has significantly improved in recent years, due to novel agents that are available for treatment. The anti-CD38 monoclonal antibody Daratumumab is particularly efficient for patients with relapse/refractory disease, and many studies have shown its unprecedented efficacy als...

Full description

Bibliographic Details
Main Authors: Alessandro Gozzetti, Francesca Bacchiarri, Vincenzo Sammartano, Marzia Defina, Anna Sicuranza, Bianca Mecacci, Elisabetta Zappone, Emanuele Cencini, Alberto Fabbri, Donatella Raspadori, Monica Bocchia
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Oncology
Subjects:
Daratumumab
multiple myeloma
rapid infusion
safety
efficacy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.570187/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.570187/full

Similar Items